US FDA clears Lantern Pharma and Starlight Therapeutics’ IND for a planned phase 1 paediatric CNS cancer trial of STAR-001: Dallas Monday, March 30, 2026, 14:00 Hrs [IST] Lanter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results